Comparison of the Safety of Q8003 Versus Morphine Equivalent Doses of Its Components (Oxycodone and Morphine) in Bunionectomy Patients
This study has been completed.
Sponsor:
QRxPharma Inc.
Information provided by (Responsible Party):
QRxPharma Inc.
ClinicalTrials.gov Identifier:
NCT01280331
First received: January 18, 2011
Last updated: May 15, 2012
Last verified: May 2012
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This is a randomized, double-blind, multicenter, repeat-dose study of fixed doses of Q8003 12 mg/8 mg given q6hr compared to morphine sulfate 24 mg and oxycodone hydrochloride 16 mg given q6hr for the management of acute moderate to severe postoperative pain for 48 hours following bunionectomy surgery.
| Condition | Intervention | Phase |
|---|---|---|
|
Postoperative Pain |
Drug: Q8003 (morphine sulfate and oxycodone hydrochloride) Drug: Morphine sulfate Drug: Oxycodone HCl |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | A Randomized, Double-Blind, Multi-Center, Repeat-Dose, Comparison of the Effects of Q8003 to the Morphine-Equivalent Doses of Oxycodone and of Morphine on the Opioid-Related Adverse Events of Moderate to Severe Nausea, Emesis, and Dizziness in Subjects With Acute Moderate-to-Severe Postoperative Pain Following Bunionectomy Surgery |
Resource links provided by NLM:
Further study details as provided by QRxPharma Inc.:
Primary Outcome Measures:
- Differences in desaturation events per standardized time unit [ Time Frame: 48 hours ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Difference in efficacy between Q8003 and its components (morphine and oxycodone) [ Time Frame: 48 hours ] [ Designated as safety issue: No ]Changes from baseline in pain intensity
- Differences in the absence of emesis without the use of an anti-emetic (emesis complete response) [ Time Frame: 48 hours ] [ Designated as safety issue: Yes ]
| Enrollment: | 375 |
| Study Start Date: | January 2011 |
| Study Completion Date: | April 2011 |
| Primary Completion Date: | April 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Q8003 12 mg/8 mg
Combination
|
Drug: Q8003 (morphine sulfate and oxycodone hydrochloride)
Two Q8003 6 mg/4 mg IR Capsules q6h
|
|
Active Comparator: Morphine sulfate 24 mg
Single component
|
Drug: Morphine sulfate
Two morphine sulfate 12 mg IR capsules q6h
|
|
Active Comparator: Oxycodone HCl 16 mg
Single component
|
Drug: Oxycodone HCl
Two oxycodone HCl 8 mg IR Capsules q6h
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patient is male or female and at least 18 years of age.
- Females must be non-pregnant, non-lactating, and practicing an acceptable method of birth control, or be surgically sterile or postmenopausal (amenorrhea for ≥ 12 months). Non-pregnancy will be confirmed by pregnancy tests conducted at Screening and Pre-treatment.
- Patient is scheduled for bunionectomy surgery, meets the criteria of an ASA Class I to III, and is willing to stay in the study center for at least 48 hours from the initial dose of study medication post surgery.
- To be randomized after surgery, the patient must report moderate to severe pain (a score of 2 or more on the 4 point Likert scale or 4 or more on the 11 point NPRS scale).
- At least 40% of study subjects will be 60 years of age or older.
Exclusion Criteria:
- In the opinion of the Investigator, has a history of pulmonary, cardiovascular (including uncontrolled hypertension), neurologic, endocrine, hepatic, gastrointestinal, or kidney disease or therapy that would jeopardize the patient's well being by participation in this study or is mentally or emotionally unsuitable to participate, or unable/unwilling to comply with the study assessments.
- Used opiates continuously (including tramadol) for more than ten days in the past year.
- Hypersensitivity or poor tolerance to acetaminophen.
- Currently receiving any medications that are not at a stable dose (the same dose for > 2 months prior to date of surgery).
- Was dosed with another investigational drug within 30 days prior to the Screening Visit or has previously received treatment with Q8003.
- Current therapy with central nervous system depressant medications that might increase the risks of treatment with opioids (other than those used with surgical anesthesia).
- Current evidence of alcohol abuse (regularly drinks more than 4 units of alcohol per day; 1 unit = ½ pint of beer, 1 glass of wine, or 1 ounce of spirit).
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01280331
Locations
| United States, California | |
| Investigational site | |
| Anaheim, California, United States, 92801 | |
| United States, Maryland | |
| Investigational site | |
| Owings Mills, Maryland, United States, 21117 | |
| Investigational site | |
| Pasadena, Maryland, United States, 21122 | |
| United States, Texas | |
| Investigational Site | |
| San Antonio, Texas, United States, 78229 | |
Sponsors and Collaborators
QRxPharma Inc.
Investigators
| Study Director: | Patricia T. Richards, MD, Ph.D. | QRxPharma Inc. |
More Information
No publications provided
| Responsible Party: | QRxPharma Inc. |
| ClinicalTrials.gov Identifier: | NCT01280331 History of Changes |
| Other Study ID Numbers: | Q8003-022 |
| Study First Received: | January 18, 2011 |
| Last Updated: | May 15, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by QRxPharma Inc.:
|
Bunionectomy |
Additional relevant MeSH terms:
|
Pain, Postoperative Postoperative Complications Pathologic Processes Pain Signs and Symptoms Morphine Oxycodone Analgesics, Opioid Analgesics |
Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Central Nervous System Depressants Narcotics |
ClinicalTrials.gov processed this record on May 23, 2013